← 返回

人树突状细胞免疫疗法在胃肠道肿瘤治疗中的进展

英文原题:Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer.

查看英文原题

Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer.

PubMed 2022/05/10(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

树突状细胞(DCs)是最强的抗原呈递细胞,是在抗击癌症中协调免疫系统的焦点。阐明DCs细胞生物学的基础科学研究已促成了这场斗争中的新策略,包括癌症疫苗学、联合治疗和过继细胞治疗。尽管免疫治疗目前正成为前所未有的从实验室到临床的成功,但当前免疫治疗在胃肠道(GI)癌症患者中的总体缓解率相当低。在此,我们对DCs在GI癌症患者治疗中的研究进行了文献检索。我们提供了基于DC的免疫治疗的进展,并重点介绍了表明每种疫苗相关治疗疗效和毒性的临床试验。此外,我们还提出了基于DC的免疫治疗尚未解决的问题。本研究主要关注来自人类研究的数据,以帮助理解DCs在GI癌症患者中的参与。

展开英文摘要原文

Dendritic cells (DCs), the strongest antigen-presenting cells, are a focus for orchestrating the immune system in the fight against cancer. Basic scientific investigations elucidating the cellular biology of the DCs have resulted in new strategies in this fight, including cancer vaccinology, combination therapy, and adoptive cellular therapy. Although immunotherapy is currently becoming an unprecedented bench-to-bedside success, the overall response rate to the current immunotherapy in patients with gastrointestinal (GI) cancers is pretty low.

Here, we have carried out a literature search of the studies of DCs in the treatment of GI cancer patients.

We provide the advances in DC-based immunotherapy and highlight the clinical trials that indicate the therapeutic efficacies and toxicities related with each vaccine.

Moreover, we also offer the yet-to-be-addressed questions about DC-based immunotherapy.

This study focuses predominantly on the data derived from human studies to help understand the involvement of DCs in patients with GI cancers.

论文信息

作者
Ni L
单位
Institute for Immunology and School of Medicine, Tsinghua University, Beijing, China.China
文献类型
综述 · 非美国政府资助研究
期刊
Frontiers in immunology2022
原文标识
PubMed 35619702 · DOI 10.3389/fimmu.2022.887189